SAN RAMON, Calif., May 25, 2021 /PRNewswire/ -- CooperVision
Specialty EyeCare's Procornea DreamLite®
night lenses have received European approval for slowing the
progression of myopia in children and young adults. The popular
orthokeratology contact lens is the latest CooperVision myopia
control product to gain the CE Mark, joining EyeDream and Paragon
CRT® ortho-k designs,
MiSight® 1 day soft contact lenses, and
SightGlass Vision Diffusion Optics Technology spectacle lenses.
CooperVision has built the world's largest portfolio of
evidence-based myopia control interventions. This provides eye care
professionals (ECPs) with multiple approved options for addressing
the global myopia epidemic, helping them tailor the approach to
each child and family.
"Myopia's increasing frequency and prevalence is one of the most
discussed issues in eye health. But conversation without action
will not change the lives of the hundreds of millions of children
affected by the issue. That sentiment is echoed by the World
Council of Optometry, which recently passed a resolution advising
optometrists to incorporate a standard of care for myopia
management within their practices," said Dr. Juan Carlos Aragón,
President, CooperVision Specialty EyeCare.
"Our commitments to innovations such as
DreamLite® night lenses, providing broader
access to optical interventions with scientifically-demonstrated
outcomes, and investing in widespread education for eye care
professionals and parents are examples why CooperVision continues
to lead the myopia management category. The latest CE Mark will
help ECPs communicate with even more confidence about
DreamLite® lenses' ability to slow the
progression of myopia."
DreamLite® night lenses can be used for myopia
control with children who have a refraction of -0.75 D to -5.00 D
and a cylindrical refraction with a maximum of -2.50 D. A two-year
study showed that DreamLite® night lenses reduced
axial length growth by 63% percent among high myopes compared to
the single vision spectacle lens control group—a total reduction of
0.32 mm.1 The lenses are currently available across
Europe, the Middle East, and China.
CooperVision products are used by thousands of ECPs across the
region for myopia correction and control. DreamLite®
ortho-k lenses represent the leading design in the United Kingdom (under the EyeDream brand), and
MiSight® 1 day soft contact lenses are available in
multiple countries for daily wear. Commercialization plans are in
progress for SightGlass Vision Diffusion Optics
Technology™ spectacle lenses, which CooperVision
acquired earlier this year.
In November 2019,
MiSight® 1 day became the first and only U.S. Food and
Drug Administration-approved* soft contact lenses proven
to slow myopia progression in children, aged 8-12 at the initiation
of treatment.2** This pivotal development and subsequent
adoption by thousands of influential ECPs has accelerated myopia
management in the U.S. and other countries.
Myopia is projected to affect the vision of approximately five
billion people globally by 2050, more than doubling today's
numbers.3 High myopia raises the risk of
vision-threatening eye conditions such as retinal detachment,
glaucoma, early cataracts and myopic maculopathy, a leading cause
of blindness world-wide.4
* U.S. indications for use: MiSight® 1
day (omafilcon A) soft (hydrophilic) contact lenses for daily wear
are indicated for the correction of myopic ametropia and for
slowing the progression of myopia in children with non-diseased
eyes, who at the initiation of treatment are 8-12 years of age and
have a refraction of -0.75 to -4.00 diopters (spherical equivalent)
with ≤ 0.75 diopters of astigmatism. The lens is to be discarded
after each removal.
** Compared to a single vision 1 day lens over a 3-year
CooperVision, a division of
CooperCompanies (NYSE: COO), is one of the world's leading
manufacturers of contact lenses. The company produces a full array
of daily disposable, two-week and monthly soft contact lenses that
feature advanced materials and optics, and premium rigid gas
permeable lenses for orthokeratology and scleral designs.
CooperVision has a strong heritage of addressing the toughest
vision challenges such as astigmatism, presbyopia, childhood
myopia, and highly irregular corneas; and offers the most complete
portfolio of spherical, toric and multifocal products available.
Through a combination of innovative products and focused
practitioner support, the company brings a refreshing perspective
to the marketplace, creating real advantages for customers and
wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a
global medical device company publicly traded on the NYSE
(NYSE:COO). Cooper operates through two business units,
CooperVision and CooperSurgical. CooperVision brings a refreshing
perspective on vision care with a commitment to developing a wide
range of high-quality products for contact lens wearers and
providing focused practitioner support. CooperSurgical is committed
to advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of
more than 12,000 with products sold in over 100 countries. For more
information, please visit www.coopercos.com.
McDougall, McDougall Communications for CooperVision
email@example.com or +1-585-434-2150
1 Charm J, Cho P.
High myopia-partial reduction ortho-k: a 2-year randomized
study. Optom Vis Sci. 2013 Jun;90(6):530-9. doi:
10.1097/OPX.0b013e318293657d. PMID: 23645372.
2 Chamberlain P, et al. A 3-year randomized
clinical trial of MiSight® lenses for myopia control. Optom Vis
Sci. 2019; 96(8):556-67.
3 Holden et al, - Global Prevalence of myopia
and high myopia and temporal trends from 2000 through 2050.
Ophthalmology 2016. 123(5):1036-1042
4 Tideman JW et al. Association of axial length
with risk of uncorrectable visual impairment for Europeans with
myopia. JAMA Ophthalmol. 2016;134:1355-1363.